Follicular lymphoma, survival, and rituximab: Is it time to declare victory?

被引：18

作者：

Horning, Sandra J. ^{[1
]}

机构：

[1] Stanford Univ, Ctr Med, Stanford, CA 94305 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 28期

关键词：

D O I：

10.1200/JCO.2008.16.1398

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：4537 / 4538

页数：2

共 11 条

[1] New treatment options have changed the survival of patients with follicular lymphoma [J].

Fisher, RI ;

LeBlanc, M ;

Press, OW ;

Maloney, DG ;

Unger, JM ;

Miller, TP .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) :8447-8452

[2] Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma:: An East German Study Group hematology and oncology study [J].

Herold, Michael ;

Haas, Antje ;

Srock, Stefanie ;

Neser, Sabine ;

Al-Ali, Kathrin Haifa ;

Neubauer, Andreas ;

Doelken, Gottfried ;

Naumann, Ralph ;

Knauf, Wolfgang ;

Freund, Mathias ;

Rohrberg, Robert ;

Hoeffken, Klaus ;

Franke, Astrid ;

Ittel, Thomas ;

Kettner, Erika ;

Haak, Ursula ;

Mey, Ulrich ;

Klinkenstein, Christian ;

Assmann, Michael ;

von Gruenhagen, Ullrich .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) :1986-1992

[3] Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [J].

Hiddemann, W ;

Kneba, M ;

Dreyling, M ;

Schmitz, N ;

Lengfelder, E ;

Schmits, R ;

Reiser, M ;

Metzner, B ;

Harder, H ;

Hegewisch-Becker, S ;

Fischer, T ;

Kropff, M ;

Reis, HE ;

Freund, M ;

Wörmann, B ;

Fuchs, R ;

Planker, M ;

Schimke, J ;

Eimermacher, H ;

Trümper, L ;

Aldaoud, A ;

Parwaresch, R ;

Unterhalt, M .

BLOOD, 2005, 106 (12) :3725-3732

[4]

Hochster HS, 2005, BLOOD, V106, p106A

[5]

HORNING SJ, 1993, SEMIN ONCOL, V20, P75

[6] Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage [J].

Ladetto, Marco ;

De Marco, Federica ;

Benedetti, Fabio ;

Vitolo, Umberto ;

Patti, Caterina ;

Rambaldi, Alessandro ;

Pulsoni, Alessandro ;

Musso, Maurizio ;

Liberati, Anna M. ;

Olivieri, Attilio ;

Gallamini, Andrea ;

Pogliani, Enrico ;

Scalabrini, Delia Rota ;

Callea, Vincenzo ;

Di Raimondo, Francesco ;

Pavone, Vincenzo ;

Tucci, Alessandra ;

Cortelazzo, Sergio ;

Levis, Alessandro ;

Boccadoro, Mario ;

Majolino, Ignazio ;

Pileri, Alessandro ;

Gianni, Alessandro M. ;

Passera, Roberto ;

Corradini, Paolo ;

Tarella, Corrado .

BLOOD, 2008, 111 (08) :4004-4013

[7] Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M.D. Anderson Cancer Center [J].

Liu, Q ;

Fayad, L ;

Cabanillas, F ;

Hagemeister, FB ;

Ayers, GD ;

Hess, M ;

Romaguera, J ;

Rodriguez, MA ;

Tsimberidou, AM ;

Verstovsek, S ;

Younes, A ;

Pro, B ;

Lee, MS ;

Ayala, A ;

McLaughlin, P .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (10) :1582-1589

[8] Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma [J].

Marcus, Robert ;

Imrie, Kevin ;

Solal-Celigny, Philippe ;

Catalano, John V. ;

Dmoszynska, Anna ;

Raposo, Joao C. ;

Offner, Fritz C. ;

Gomez-Codina, Jose ;

Belch, Andrew ;

Cunningham, David ;

Wassner-Fritsch, Elisabeth ;

Stein, George .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4579-4586

[9]

Salles G, 2007, BLOOD, V110, p792A

[10] Improved survival of follicular lymphoma patients in the United States [J].

Swenson, WT ;

Wooldridge, JE ;

Lynch, CF ;

Forman-Hoffman, VL ;

Chrischilles, E ;

Link, BK .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5019-5026

← 1 2 →